SANDHYA GIRISH, PhD
IQ Board of Directors Member (2019-2020)
IQ Clinical Pharmacology Leadership Group (CPLG) Chair (2019-2020)
IQ CPLG Vice Chair (2018)
IQ CPLG Member (2016-Present)
Vice President, Clinical Pharmacology, Gilead
PhD, Biomedical Sciences, Northeastern University
IS THERE A "SPECIAL SAUCE" THAT HELPS THE GROWTH OF IQ?
The support provided by Faegre Drinker Biddle & Reath LLP as IQ Secretariat and Legal Counsel is absolutely critical to the success of IQ and Clinical Pharmacology Leadership Group (CPLG). The leaders across various member companies have time constraints and the support provided by the Secretariat advances the vision and mission of CPLG.
HOW HAVE YOUR COMPANY AND COLLEAGUES BENEFITTED FROM IQ ENGAGEMENT?
The various Working Groups (WG) (e.g., ADC, MABEL, QSP, organ impairment, novel modalities, immunogenicity) have all enabled robust discussions amongst subject matter experts and these WGs have arrived with best practices and that has been enormously helpful. Additionally, clinical pharmacology continues to evolve (e.g., novel modalities, immunogenicity issues, new pharmacometrics approaches). This requires member companies to work together to address new drug development challenges.
IN YOUR EXPERIENCE, WHAT ARE IQ’S GREATEST ACCOMPLISHMENTS?
As a former Chair of CPLG, I am very proud of our outreach to Japan PMDA and having our first scientific exchange with PMDA in 2020. Additionally, I am very proud of the IQ/FDA scientific exchanges over the past several years. We have discussed various scientific topics of mutual interest to advance clinical pharmacology.